Company: ZVRA
Filing Date: 2025-04-10
Form Type: PREC14A
Source: 0000897069-25-000784
Chunk: 9

Company: ZEVRA THERAPEUTICS, INC.
Filing Date: 2025-04-10
Form: PREC14A
Chunk 9
---
 Favorito or Wendy Dixon, Ph.D. (the two incumbent directors whose terms were set to expire at the Annual Meeting and who are nominated by the Board for re-election at the Annual Meeting), provided that the Board also supports Dr. Mickle (the “ Updated Mangless Offer”). On March 21, 2025, Mr. DeBoom sent an email to Mr. Thompson, copying a representative of Latham & Watkins LLP, to reiterate the Updated Mangless Offer. On March 24, 2025, Mr. Thompson sent an email to Mr. DeBoom, copying a representative of Latham & Watkins LLP, providing Mr. Mangless with the required notification of the Company’s nominees for election at the Annual Meeting, Ms. Favorito and Dr. Dixon, pursuant to Rule 14a-19(d) under the Exchange Act. On March 31, 2025, the Company filed a preliminary proxy statement with the U.S. Securities and Exchange Commission (“ SEC”) in connection with the 2025 Annual Meeting. On April 10, 2025, the Proponent filed a preliminary proxy statement with the SEC in connection with the Annual Meeting followed by a press release to the stockholders of the Company. 7 REASONS FOR OUR SOLICITATION We believe Zevra is dramatically undervalued and our goal is to help the Company reach its full potential. Zevra has a troubling history of underperformance and poor corporate governance practices and the stockholders have long suffered under the leadership of the current Board of Directors. Fortunately, this year you have the power to effect change at Zevra by voting for directors of the Company other than the members of the current Board of Directors. Specifically, we offer you a choice—an ability to vote for two exceptionally qualified director nominees who have the skills and commitment to help maximize stockholder value and realize Zevra’s true potential. This campaign is the result of careful consideration of the factors hampering Zevra’s potential under its current Board of Directors and lack of governance and the belief that adding the Nominees to the Board of Directors would bring sorely needed governance and be an effective contribution towards enhancing key strategic, operating and financial capabilities that would in turn improve stakeholder value. The Nominees recognize fully that as members of the Board they will owe fiduciary duties to all Zevra’s stockholders and are committed to maximizing value for all Zevra stockholders. The Proponent reserves the right to nominate additional nominees for any reason